tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

BCAX Stock Latest News

Promising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
RatingsPromising Drug Pipeline and Upcoming Trial Data Support Buy Rating for Bicara Therapeutics
3d ago
BCAX
Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)
PremiumThe Fly
Bicara Therapeutics reports Q3 EPS (67c), consensus (53c)
4d ago
BCAX
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
PremiumCompany Announcements
Bicara Therapeutics’ FORTIFI-HN01 Study: A Promising Step in Cancer Treatment
17d ago
BCAX
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
PremiumCompany Announcements
Bicara Therapeutics’ Innovative Approach to EGFR-Driven Tumors: A Clinical Study Update
17d ago
BCAX
Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating
PremiumRatings
Bicara Therapeutics: Strategic Advantages and Favorable Safety Profile Drive Buy Rating
24d ago
BCAX
Bicara sinks after J&J reports head and neck cancer data
PremiumThe FlyBicara sinks after J&J reports head and neck cancer data
24d ago
JNJ
BCAX
Bicara Therapeutics management to meet with Cantor Fitzgerald
Premium
The Fly
Bicara Therapeutics management to meet with Cantor Fitzgerald
30d ago
BCAX
Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
Premium
The Fly
Bicara Therapeutics announces ficerafusp alfa granted BTD by U.S. FDA
1M ago
BCAX
Bicara Therapeutics files $400M mixed securities shelf
PremiumThe Fly
Bicara Therapeutics files $400M mixed securities shelf
1M ago
BCAX
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
PremiumRatings
Promising Market Opportunity for Bicara Therapeutics in HPV-Negative Head & Neck Cancer Warrants Buy Rating
1M ago
BCAX
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
PremiumRatings
Optimistic Buy Rating for Bicara Therapeutics: Superior Clinical Benefits and Valuation Upside
2M ago
BCAX
Bicara Therapeutics initiated with a Buy at JonesResearch
PremiumThe Fly
Bicara Therapeutics initiated with a Buy at JonesResearch
2M ago
BCAX
Bicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
PremiumThe FlyBicara Therapeutics price target lowered to $40 from $41 at H.C. Wainwright
3M ago
BCAX
Bicara Therapeutics initiated with an Overweight at Piper Sandler
Premium
The Fly
Bicara Therapeutics initiated with an Overweight at Piper Sandler
3M ago
BCAX
Bicara Therapeutics initiated with an Overweight at Piper Sandler
Premium
The Fly
Bicara Therapeutics initiated with an Overweight at Piper Sandler
3M ago
BCAX
Bicara Therapeutics Reports Q2 2025 Results and Progress
PremiumCompany Announcements
Bicara Therapeutics Reports Q2 2025 Results and Progress
3M ago
BCAX
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
PremiumRatings
Promising Clinical Developments and Financial Stability Drive Buy Rating for Bicara Therapeutics
3M ago
BCAX
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)
PremiumThe Fly
Bicara Therapeutics reports Q2 EPS (50c), consensus (54c)
3M ago
BCAX
Bicara Therapeutics expects cash to fund operations into 1H of 2029
PremiumThe Fly
Bicara Therapeutics expects cash to fund operations into 1H of 2029
3M ago
BCAX
Bicara Therapeutics Elects New Directors at Annual Meeting
PremiumCompany AnnouncementsBicara Therapeutics Elects New Directors at Annual Meeting
5M ago
8K
BCAX
Bicara Therapeutics Expands Boston Headquarters with New Lease
Premium
Company Announcements
Bicara Therapeutics Expands Boston Headquarters with New Lease
5M ago
8K
BCAX
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
Premium
Ratings
Promising Potential of Bicara Therapeutics’ Ficerafusp Alfa: Analyst Reiterates Buy Rating with Strong Clinical Results and $41 Price Target
5M ago
BCAX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >